🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans

Thomas Deal

Stock Analyst at Raymond James

(1.24)
# 3,782
Out of 5,189 analysts
6
Total ratings
66.7%
Success rate
-8.6%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Thomas Deal

Kymera Therapeutics
Oct 29, 2026
Reiterated: Buy
Price Target: $140 → $144
Current: $115.31
Upside: +24.88%
Nektar Therapeutics
Oct 8, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $30.20
Upside: -
Odyssey Therapeutics
Oct 8, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $16.96
Upside: +147.64%
Palisade Bio
Oct 8, 2026
Initiated Coverage: Buy
Price Target: $6
Current: $0.8399
Upside: +614.37%